

FORMATO EUROPEO
PER IL CURRICULUM
VITAE



INFORMAZIONI PERSONALI

Nome	LUPPI FABRIZIO
Indirizzo	
Telefono	
Fax	
E-mail	fabrizio.luppi@unimib.it
Nazionalità	Italiana
Data di nascita	

ESPERIENZA LAVORATIVA

1. **Professore Ordinario** (settore concorsuale 06/D1 – Malattie dell’Apparato Cardiovascolare e Malattie dell’Apparato Respiratorio – SSD MED/10) presso l’Università degli Studi di Milano Bicocca, con integrazione assistenziale presso la Clinica Pneumologica della Fondazione IRCCS “S. Gerardo dei Tintori” a Monza (01 Ottobre 2024- presente).
2. **Direttore S.C. Pneumologia – Fondazione IRCCS San Gerardo dei Tintori, Monza**
(1 agosto 2022– presente).
3. **Direttore f.f. - S.C. Pneumologia – Fondazione IRCCS San Gerardo dei Tintori, Monza**
(1 novembre 2021– 31 luglio 2022).
4. **Direttore Scuola di Specializzazione in Malattie dell’Apparato Respiratorio dell’Università degli Studi di Milano Bicocca** (01 novembre - presente).
5. **Professore Associato** (settore concorsuale 06/D1 – Malattie dell’Apparato Cardiovascolare e Malattie dell’Apparato Respiratorio – SSD MED/10)

presso l'Università degli Studi di Milano Bicocca, con integrazione assistenziale presso la Clinica Pneumologica dell'Ospedale "S. Gerardo" – ASST Monza (20 dicembre 2018 – 30 Settembre 2024).

6. **Unità Operativa Semplice** "Centro Malattie Rare del Polmone" dell'Azienda Ospedaliero – Universitaria di Modena (16 ottobre 2013 – 19 dicembre).
7. **Medico di 1° Livello Dirigenziale** a tempo indeterminato presso la UOC di Malattie dell'Apparato Respiratorio dell'Azienda Ospedaliero – Universitaria di Modena (01 gennaio 2007 – 19 dicembre 2018).
8. **Ufficiale Medico di Complemento** presso l'Infermeria Presidiaria del Distretto Militare di Bologna con l'incarico di "Dirigente del Servizio Sanitario e Capo Ufficio Sanitario" (08 aprile 1994 – 24 aprile 1995).

ISTRUZIONE E FORMAZIONE

1. **Dottorato di Ricerca in Fisiopatologia Respiratoria Sperimentale** conseguito il 21 aprile 2005 presso l'Università degli Studi di Parma discutendo una tesi dal titolo "Role of epithelial cells and fibroblasts in cigarette smoke – induced lung injury and repair" (Relatore: Prof. L. M. Fabbri).
2. **Research Fellow** presso il Laboratorio di "Biologia Cellulare Respiratoria e Immunologia" (Diretto dal Prof. P. S. Hiemstra) del Dipartimento di Pneumologia dell'Università degli Studi di Leiden, Olanda (Diretto dal Prof. K.F. Rabe (1 febbraio 2001 – 1 gennaio 2003).
3. **Specializzazione in Malattie dell'Apparato Respiratorio** (indirizzo Malattie dell'Apparato Respiratorio e Tisiologia), conseguita il 3 novembre 1998 presso l'Università degli Studi di Modena con la votazione con la votazione 50/50, discutendo una tesi dal titolo "Fagocitosi, "killing" intracellulare e rilascio di anione superossido da parte dei macrofagi alveolari in corso di

sarcoidosi, alveolite fibrosante criptoenergetica e sclerodermia” (Relatore: Prof. G. Velluti).

4. **Laurea in Medicina e Chirurgia** presso l’Università degli Studi di Modena, conseguita il 19 marzo 1993 con la votazione di 110/110 e lode discutendo una tesi dal titolo: “La tubercolosi polmonare ed extrapolmonare negli immigrati extracomunitari: nostre esperienze” (Relatore: Prof. G. Velluti).

CAPACITÀ E COMPETENZE PERSONALI
Acquisite nel corso della vita e della carriera ma non necessariamente riconosciute da certificati e diplomi ufficiali.

Endoscopia bronchiale, ventilazione meccanica non invasiva, diagnosi, monitoraggio e trattamento delle patologie ostruttive bronchiali, diagnosi, monitoraggio e trattamento delle pneumopatie diffuse interstiziali.

MADRELINGUA

ITALIANA

LINGUE STRANIERE

INGLESE

- Capacità di lettura
- Capacità di scrittura
- Capacità di espressione orale

ECCELLENTE

BUONA

BUONA

PREMI E BORSE DI STUDIO

PREMIO "GIOVANI RICERCATORI" AL 4° CONGRESSO "ASMA BRONCHIALE: NUOVI OBIETTIVI, NUOVI RIMEDI" PER LO STUDIO "ESPRESSIONE DI IL-4, IL-13 ED IFN- γ NELLE VIE AEREE CENTRALI DI FUMATORI CON SINTOMI DI BRONCHITE CRONICA" (VERONA 28-30 NOVEMBRE 2000).

BORSA DI STUDIO DELLA NETHERLANDS ASTHMA FOUNDATION (NAF #98.12) CONSEGUITA PER IL PROGETTO: "THE ROLE OF EPIDERMAL GROWTH FACTORS AND THEIR RECEPTORS IN THE PATHOGENESIS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE" (DIPARTIMENTO DI PNEUMOLOGIA DELL'UNIVERSITÀ DEGLI STUDI DI LEIDEN, OLANDA) SOTTO LA SUPERVISIONE DEL PROF. PIETER S. HIEMSTRA (1 FEBBRAIO 2001 – 31 DICEMBRE 2001)

BORSA DI STUDIO DELLA EUROPEAN RESPIRATORY SOCIETY (LONG TERM RESEARCH FELLOWSHIP, LTRF-2001-026) PER IL PROGETTO: "EPITHELIAL WOUND REPAIR IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE: THE ROLE OF CIGARETTE SMOKE, EPIDERMAL GROWTH FACTOR AND CHEMOKINES" (DIPARTIMENTO DI PNEUMOLOGIA DELL'UNIVERSITÀ DEGLI STUDI DI LEIDEN, OLANDA) SOTTO LA SUPERVISIONE DEL PROF. KLAUS F. RABE (01 GENNAIO 2002 AL 31 DICEMBRE 2002)

BORSA DI STUDIO U.I.P. (UNIONE ITALIANA PNEUMOLOGIA) CONSEGUITA PER IL PROGETTO "DANNO POLMONARE CAUSATO DA ROS: PROTEZIONE E TRATTAMENTO", (DIPARTIMENTO DI PNEUMOLOGIA DELL'UNIVERSITÀ DEGLI STUDI DI LEIDEN, OLANDA) SOTTO LA SUPERVISIONE DEL PROF. PIETER S. HIEMSTRA DAL 01-01-2002 AL 31-12-2002

Fondazione IRCCS San Gerardo dei Tintori

sede legale

20900 Monza (MB) - Via G. Pergolesi, 33 - Tel. 039.233.1 Fax 039.233.9775 – www.asst-monza.it
P.IVA 12698710964 C.F. 12698710964

PARTECIPAZIONE A STUDI
CLINICI NAZIONALI E
INTERNAZIONALI

2003-2008: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Safety and Efficacy of Interferon gamma-1b in Patients with Idiopathic Pulmonary Fibrosis (The INSPIRE Trial) (Sponsor InterMune Inc. USA): Coordinator Study.

2006-2009: A Randomized, Double-Blind, Placebo-Controlled, Phase 3, Three arm Study of the Safety and Efficacy of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (The CAPACITY Trial) (Sponsor InterMune Inc. USA): Coordinator Study.

2007-2010: A 12 month, double blind, randomized, placebo-controlled trial evaluating the effect of BIBF 1120 administered at oral doses of 50 mg qd, 50 mg bid, 100 mg bid and 150 mg bid on Forced Vital Capacity decline during one year, in patients with Idiopathic Pulmonary Fibrosis, with optional active treatment extension until last patient out (The TOMORROW Trial) (Sponsor Boehringer Ingelheim AG): Coordinator Study.

2011-2014: Phase III, randomized double-blind placebo controlled study to assess the efficacy of tyrosine kinase inhibitor in IPF (BI1199.32) (The INPULSIS Trial) (Sponsor Boehringer Ingelheim AG): site Principal Investigator

2013-2017: An open label extension trial of the long-term safety of oral BIBF 1120 in patients with Idiopathic Pulmonary Fibrosis (IPF) (BI1199.33) (Sponsor Boehringer Ingelheim AG): site Principal Investigator

2013-2014: A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of GS-6624 in Subjects with Idiopathic Pulmonary Fibrosis (RAINIER study) (Sponsor GILEAD Sciences Inc. USA): site Principal Investigator

2013-2017: A Phase II Open Label, Roll Over Study of the Long Term Tolerability, Safety and Efficacy of Oral BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis (BI1199.35) (Sponsor Boehringer Ingelheim AG): site Principal Investigator

2013-attivo: Prospective study "Correlation between lung sounds and radiographic pattern at chest high resolution CT scan" (Finanziato da Intermune/Roche con Euro 150.000): site Principal Investigator

2013-2015: Studio multicentrico dal titolo "Duration - Individualizzazione della durata della terapia antibiotica in pazienti ospedalizzati con polmonite acquisita in comunità: studio randomizzato, controllato, di non inferiorità" (Coordinatore: Prof. Francesco Blasi): site Principal Investigator

2013-2015: Studio multicentrico dal titolo: "Duration – Individualizzazione

della durata della terapia antibiotica in pazienti ospedalizzati con polmonite acquisita in comunità: studio randomizzato controllato, di non inferiorità” (Coordinatore: Prof. Francesco Blasi) site: Principal Investigator

2014-2016: Post-Authorisation Safety Study of Esbriet (Pirfenidone): A Prospective Observational Registry to Evaluate Long-Term Safety in a Real-World Setting (PASSPORT study) (Sponsor InterMune Inc. USA): site Principal Investigator

2015-2018 FIBRONET- IPF Italian observational study (studio osservazionale italiano nella fibrosi polmonare idiopatica) – Study Number 1199.262 (Sponsor Boehringer-Ingelheim): site Principal Investigator

2016-2018: Studio prospettico dal titolo "Definizione di un protocollo valutativo dell'impatto dell'esposizione professionale sulla disabilità in pazienti affetti da fibrosi polmonare idiopatica attraverso il questionario WHODAS 2.0" in collaborazione con l'Università di Ferrara: site Principal Invetsigator.

2016-2018: A 24-week, double-blind, randomized, parallel-group study evaluating the efficacy and safety of oral nintedanib coadministered with oral sildenafil, compared to treatment with nintedanib alone, in patients with idiopathic pulmonary fibrosis (IPF) and advanced lung function impairment (BI1199.36) (Sponsor Boehringer Ingelheim AG): site Principal Investigator

2016-2017: A Randomized Open-Label, Multicenter Study of LAI in Adult Patients with Nontuberculous Mycobacterial (NTM) Lung Infections caused by Mycobacterium avium Complex (MAC) thet are Refractory to Treatment (Sponsor INSMED, USA): site Principal Investigator

2016-2018: An observational, retrospective, multicenter study to evaluate the efficacy of pirfenidone administered according to clinical practice to patients with Idiopathic Pulmonary Fibrosis (Sponsorizzato da Roche S.p.A) site Principal Investigator

2017-2018: A phese IIb, multicenter, randomized, double blind, placebo controlled study to evaluate the efficacy, safety and tolerability of sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and intermediate or high probability of group 3 pulmonary hypertension (MA2997) (Sponsorizzato da Roche S.p.A.): site Principal Investigator

2017-2018: A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of nintedanib over 52 weeks in patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD): site Principal Investigator

2018-2019: An international study to characterize the disease behaviour of idiopathic pulmonary fibrosis (Studio MA39297) (Sponsor Roche S.p.A.) site: Principal Investigator

2018-2020: a subject, investigator and sponsor-blinded, randomized, placebo controlled, multicenter study to investigate efficacy, safety and tolerability of VAY736 in patients with idiopathic pulmonary fibrosis (Studio CVAY736X2207) (Sponsor Novartis S.p.A.): site Principal Investigator

2020-attivo: Registro prospettico dei pazienti ospedalizzati per infezione da COVID-19 in Italia – RECOVER- Registry for Covid-19 Emergency (Principal Investigator: Prof. Stefano Centanni) site: Principal Investigator

2021-2022: A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study of the Efficacy and the Safety and Tolerability of BMS-986278 in Participants with Pulmonary Fibrosis

2022-2023: A PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF PRM-151 IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS

2022-2023: A PHASE III OPEN-LABEL EXTENSION STUDY TO EVALUATE LONG-TERM SAFETY AND EFFICACY OF PRM-151 IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF)

ATTIVITA' SOCIETARIA ED EDITORIALE

- Socio della "British Thoracic Society" (Member N°2489) dal 1998-presente
- Socio della "European Respiratory Society" dal 2018- presente
- Socio della "Società Italiana di Medicina Respiratoria" (SIMer) dall'ottobre 1998 al dicembre 2015
- Socio della "Società Italiana Pneumologia (SIP) – Italian Respiratory Society" (IRS) dall'ottobre 2016-presente
- Membro del Consiglio Direttivo Nazionale della Società Italiana Pneumologia (SIP) – Italian Respiratory Society (IRS), con la delega a "Consigliere Rappresentante Giovani" 8dal gennaio 2019- a gennaio 2021)
- Membro del Consiglio Direttivo Nazionale della Società Italiana Pneumologia (SIP) – Italian Respiratory Society (IRS), con ruolo di Tesoriere (dal gennaio 2021-presente)
- Appartenente all' Editorial Board delle seguenti riviste:
- American Journal of Respiratory and Critical Care Medicine
- BMC Pulmonary Medicine (Senior Editor)
- The Clinical Respiratory Journal
- BioMed Research International: Pulmonology
- The Scientific World Journal: Pulmonology

SERVIZI ED INCARICHI PRESSO ENTI Membro della Commissione Regionale del Farmaco (CRF) della
Regione Emilia-
SANITARI ISTITUZIONALI Romagna (Coordinatore Dr.ssa Anna Maria Marata) (gennaio 2016-
dicembre 2022) Delibera Giunta Regionale RER Prot. GPG/2016/33).

.

.

PUBBLICAZIONI

PUBBLICAZIONI

INDICATORI BIBLIOMETRICI:

SCOPUS (23 APRILE 2024)

NUMERO DI PUBBLICAZIONI: 168

CITAZIONI GLOBALI: 4189

INDICE H: 36

ARTICOLI ORIGINALI IN RIVISTE INTERNAZIONALI CON IMPACT FACTOR

1. CASALE R, GENERINI S, LUPPI F, PIGNONE A, MATUCCI-CERINIC M. PULSE CYCLOPHOSPHAMIDE DECREASES SYMPATHETIC POSTGANGLIONIC ACTIVITY, CONTROLS ALVEOLITIS, AND NORMALIZES VASCULAR TONE DYSFUNCTION (RAYNAUD'S PHENOMENON) IN A CASE OF EARLY SYSTEMIC SCLEROSIS. ARTHRITIS RHEUM. 2004; 51: 665-669.
2. LUPPI F, CERRI S, BEGHÈ B, FABBRI LM, RICHELDI L. CORTICOSTEROID AND IMMUNOMODULATORY AGENTS IN IDIOPATHIC PULMONARY FIBROSIS. RESPIR. MED. 2004; 98: 1035-1044.
3. CARBONE R., LUPPI F, MONSELISE A, BOTTINO G. BRONCHIAL HYPERRESPONSIVENESS IN ASTHMATIC ADULTS – A LONG TERM CORRELATION STUDY. EUR. MED. PHARMACOL. SCI. 2005; 9: 125-131.
4. LUPPI F, AARBIOU J, VAN WETERING S, RAHMAN I, DE BOER WI, RABE KF, HIEMSTRA PS. EFFECTS OF CIGARETTE SMOKE CONDENSATE ON PROLIFERATION AND WOUND CLOSURE OF BRONCHIAL EPITHELIAL CELLS IN VITRO: ROLE OF GLUTATHIONE. RESPIR. RES. 2005; 6: 140.
5. RICHELDI L, LUPPI M, LOSI M, LUPPI F, POTENZA L, ROVERSI P, CERRI S, MILLINGTON K, EWER K, FABBRI LM, TORELLI G, LALVANI A. DIAGNOSIS OF TUBERCULOSIS IN HEMATOLOGICAL MALIGNANCY BY ENUMERATION OF ANTIGEN-SPECIFIC T CELLS. LEUKEMIA. 2006; 20: 379-381.
6. LUPPI F, CERRI S, RICHELDI L. STEROID AND/OR OTHER IMMUNOSUPPRESSIVE THERAPIES IN IDIOPATHIC INTERSTITIAL PNEUMONIAS: HAVE THEY STILL A ROLE? SARCOIDOSIS VASCULITIS AND DIFFUSE LUNG DISEASES. 2005; 22: S74-S84.
7. FABBRI LM, LUPPI F, BEGHÈ B, RABE KF. UPDATE IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE. AM J RESPIR CRIT CARE MED. 2006; 173: 1056-1065.
8. CARNEVALI S, LUPPI F, D'ARCA D, CAPORALI A, RUGGIERI MP, VETTORI MV, CAGLIERI A, ASTANCOLLE S, PANICO F, DAVALLI P, MUTTI A, FABBRI LM, CORTI A. CLUSTERIN DECREASES OXIDATIVE STRESS IN LUNG FIBROBLASTS EXPOSED TO CIGARETTE SMOKE. AM J RESPIR CRIT CARE MED. 2006; 174: 393-399.

9. LUPPI F, LONGO AM, DE BOER WI, RABE KF, HIEMSTRA PS. INTERLEUKIN-8 STIMULATES CELL PROLIFERATION IN NON-SMALL CELL LUNG CANCER THROUGH EPIDERMAL GROWTH FACTOR RECEPTOR TRANSACTIVATION. LUNG CANCER. 2007; 56: 25-33.
10. LUPPI F, HIEMSTRA PS. EPITHELIAL RESPONSES TO OXIDATIVE STRESS IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE: LESSONS FROM EXPRESSION PROFILING. AM J RESPIR CRIT CARE MED. 2007; 175: 527-528.
11. RABE KF, BEGHÈ B, LUPPI F, FABBRI LM. UPDATE IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE. AM J RESPIR CRIT CARE MED. 2007; 175: 1222-1232.
12. FABBRI LM, LUPPI F, BEGHÈ B, RABE KF. COMPLEX CHRONIC COMORBIDITIES OF COPD. EUR RESPIR J. 2008; 31: 204-212.
13. CRISAFULLI E, COSTI S, LUPPI F, CIRELLI G, CILIONE C, COLETTI O, FABBRI LM, CLINI E. ROLE OF COMORBIDITIES IN A COHORT OF PATIENTS WITH COPD UNDERGOING PULMONARY REHABILITATION. THORAX. 2008; 63 :487-492.
14. SARTORI G, CAVAZZA A, SGAMBATO A, MARCHIONI A, BARBIERI F, LONGO L, BAVIERI M, MURER B, MESCHIARI E, TAMBERI S, CADIOLI A, LUPPI F, MIGALDI M, ROSSI G. EGFR AND K-RAS MUTATIONS ALONG THE SPECTRUM OF PULMONARY EPITHELIAL TUMORS OF THE LUNG AND ELABORATION OF A COMBINED CLINICOPATHOLOGIC AND MOLECULAR SCORING SYSTEM TO PREDICT CLINICAL RESPONSIVENESS TO EGFR INHIBITORS. AM J CLIN PATHOL. 2009; 131: 478-89.
15. RICHELDI L, LOSI M, D'AMICO R, LUPPI M, FERRARI A, MUSSINI C, CODELUPPI M, COCCHI S, PRATI F, PACI V, MEACCI M, MECCUGNI B, RUMPIANESI F, ROVERSI P, CERRI S, LUPPI F, FERRARA G, LATORRE I, GERUNDA GE, TORELLI G, ESPOSITO R, FABBRI LM. PERFORMANCE OF TESTS FOR LATENT TUBERCULOSIS IN DIFFERENT GROUPS OF IMMUNOCOMPROMISED PATIENTS. CHEST. 2009; 136: 198-204.
16. SPAGNOLO P, LUPPI F, ROSSI G, RICHELDI L. TO BAL OR NOT TO BAL: IS THIS A PROBLEM IN DIAGNOSING IPF? AM J RESPIR CRIT CARE MED. 2009; 180: 379-80
17. PANICO F, RIZZI F, FABBRI LM, BETTUZZI S, LUPPI F. CLUSTERIN (CLU) AND LUNG CANCER. ADV CANCER RES. 2009; 105: 63-76.
18. LUPPI F, LOSI M, D'AMICO R, FABBRI LM, RICHELDI L. ENDOGENOUS BLOOD MAXIMAL INTERFERON-GAMMA MAY PREDICT RESPONSE TO INTERFERON-GAMMA 1BETA TREATMENT IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS. SARCOIDOSIS VASC DIFFUSE LUNG DIS. 2009; 26; 64-68
19. RICHELDI L, DAVIES HRHR, SPAGNOLO P, LUPPI F. CORTICOSTEROIDS FOR IDIOPATHIC PULMONARY FIBROSIS. COCHRANE DATABASE OF SYST REV. 2009, ISSUE 2
20. LUPPI F, BEGHÈ B, RICHELDI L. ACUTE EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE ARE ANTIBIOTICS NEEDED? AM J RESPIR CRIT CARE MED. 2010; 181: 102-103.

21. COLACI M, SEBASTIANI M, GIUGGIOLI D, MANFREDI A, SPAGNOLO P, LUPPI F, RICHELDI L, FERRI C. BRONCHOALVEOLAR LAVAGE AND RESPONSE TO CYCLOPHOSPHAMIDE IN SCLERODERMA ALVEOLITIS. SCAND J RHEUMATOL. 2010; 39: 155-159.
22. SPAGNOLO P, DEL GIOVANE C, LUPPI F, CERRI S, BALDUZZI S, WALTERS EH, D'AMICO R, RICHELDI L. NON-STEROID AGENTS FOR IDIOPATHIC PULMONARY FIBROSIS. COCHRANE DATABASE SYST REV. 2010 SEP 8;(9): CD003134.
23. CAVAZZA A, ROSSI G, CORRADI D, LUPPI F, CERVI G, SPAGGIARI L, FALCO F, ROGGERI A. CELLULAR NON-SPECIFIC INTERSTITIAL PNEUMONIA AS A PULMONARY MANIFESTATION OF PRIMARY BILIARY CIRRHOSIS. PATHOLOGY. 2010;42(6):596-8
24. LUPPI F, COVI M, VELLUTI G, SPAGNOLO P, FABBRI LM, RICHELDI L. CO-TRIMOXAZOLE EFFECT ON HUMAN ALVEOLAR MACROPHAGES OF AIDS PATIENTS. J BIOL REGUL HOMEOST AGENTS. 2011; 25: 461-464.
25. SPAGNOLO P, LUPPI F, ROVERSI P, CERRI S, FABBRI LM, RICHELDI L. SARCOIDOSIS: CHALLENGING DIAGNOSTIC ASPECTS OF AN OLD DISEASE. AM J MED. 2012; 125 (2): 118-125
26. CERRI S, SPAGNOLO P, LUPPI F, RICHELDI L. MANAGEMENT OF IDIOPATHIC PULMONARY FIBROSIS. CLIN CHEST MED. 2012; 33: 85-94
27. COLACI M, GIUGGIOLI D, SEBASTIANI M, MANFREDI A, VACCHI C, SPAGNOLO P, CERRI S, LUPPI F, RICHELDI L, FERRI C. LUNG CANCER IN SCLERODERMA: RESULTS FROM AN ITALIAN RHEUMATOLOGIC CENTER AND REVIEW OF THE LITERATURE. AUTOIMMUN REV. 2013; 12: 374-379
28. LUPPI F, SPAGNOLO P, CERRI S, RICHELDI L. THE BIG CLINICAL TRIALS IN IDIOPATHIC PULMONARY FIBROSIS. CURR OPIN PULM MED. 2012; 18: 428-432
29. SPAGNOLO P, LUPPI F, CERRI S, RICHELDI L. GENETIC TESTING IN DIFFUSE PARENCHYMAL LUNG DISEASE. ORPHANET J RARE DIS. 2012; 7: 79
30. SPAGNOLO P, LUPPI F, RICHELDI L. THE REPLY. AM J MED. 2013; 126: E19
31. PANICO F, CASALI C, ROSSI G, RIZZI F, MORANDI U, BETTUZZI S, DAVALLI P, CORBETTA L, STORELLI ES, CORTI A, FABBRI LM, ASTANCOLLE S, LUPPI F. PROGNOSTIC ROLE OF CLUSTERIN IN RESECTED ADENOCARCINOMAS OF THE LUNG. LUNG CANCER. 2013; 79: 294-299
32. SABATINI F, LUPPI F, PETECCHIA L, STEFANO AD, LONGO AM, EVA A, VANNI C, HIEMSTRA PS, STERK PJ, SORBELLO V, FABBRI LM, ROSSI GA, RICCIARDOLO FL. BRADYKININ-INDUCED ASTHMATIC FIBROBLAST/MYOFIBROBLAST ACTIVITIES VIA BRADYKININ B2 RECEPTOR AND DIFFERENT MAPK PATHWAYS. EUR J PHARMACOL. 2013; 710: 100-109.

33. CORBETTA L, MONTINARO F, ROGASI PG, LUPPI F, MAGNI C, PAIANO S, TOFANI A, PISTOLESI M. IMPROVEMENT IN TUBERCULAR CAVITIES FOLLOWING ADJUVANT TREATMENT WITH ENDOBRONCHIAL VALVES: A CASE REPORT. *INT J TUBERC LUNG DIS.* 2013; 17: 850-851

34. SPAGNOLO P, LUPPI F, MAHER TM, WUYTS WA, GRUTTERS JC. PRIMARY ENDPOINTS IN PHASE 3 CLINICAL TRIALS IN IDIOPATHIC PULMONARY FIBROSIS: ONE STEP AT A TIME. *AM J RESPIR CRIT CARE MED.* 2013; 187: 1271-1272.

35. PINI P, BETTUA C, ORSI CF, VENTURELLI C, FAGLIONI L, FORGHIERI F, BIGLIARDI S, LUPPI F, GIRARDIS M, BLASI E. CLINICAL PERFORMANCE OF A COMMERCIAL REAL-TIME PCR ASSAY FOR ASPERGILLUS DNA DETECTION IN SERUM SAMPLES FROM HIGH-RISK PATIENTS: COMPARISON WITH A GALACTOMANNAN ENZYME IMMUNOASSAY. *EUR J CLIN MICROBIOL INFECT DIS.* 2015; 34: 131-136

36. COLACI M, GIUGGIOLI D, SEBASTIANI M, MANFREDI A, LUMETTI F, LUPPI F, CERRI S, FERRI C. PREDICTIVE VALUE OF ISOLATED DLCO REDUCTION IN SYSTEMIC SCLEROSIS PATIENTS WITHOUT CARDIO-PULMONARY INVOLVEMENT AT BASELINE. *REUMATISMO.* 2015; 67: 149-155

37. LUPPI F, CERRI S, TADDEI S, FERRARA G, COTTIN V. ACUTE EXACERBATION OF IDIOPATHIC PULMONARY FIBROSIS: A CLINICAL REVIEW. *INTERN EMERG MED.* 2015; 10: 401-411

38. ORSI CF, BETTUA C, PINI P, VENTURELLI C, LA REGINA A, MORACE G, LUPPI M, FORGHIERI F, BIGLIARDI S, LUPPI F, CODELUPPI M, GIRARDIS M, BLASI E. DETECTION OF PNEUMOCYSTIS JIROVECI AND ASPERGILLUS SPP. DNA IN BRONCHOALVEOLAR LAVAGE FLUIDS BY COMMERCIAL REAL-TIME PCR ASSAYS: COMPARISON WITH CONVENTIONAL DIAGNOSTIC TESTS. *NEW MICROBIOL.* 2015; 38: 75-84

39. VERDURI A, LUPPI F, D'AMICO R, BALDUZZI S, VICINI R, LIVERANI A, RUGGIERI V, PLEBANI M, BARBARO MP, SPANEVELLO A, CANONICA GW, PAPI A, FABBRI LM, BEGHÈ B; FARM58J2XH STUDY GROUP. ANTIBIOTIC TREATMENT OF SEVERE EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE WITH PROCALCITONIN: A RANDOMIZED NONINFERIORITY TRIAL. *PLOS ONE.* 2015; 10: e0118241.

40. SGALLA G, CERRI S, FERRARI R, RICCHIERI MP, POLETTI S, ORI M, GARUTI M, MONTANARI G, LUPPI F, PETROPULACOS K, RICHELDI L. MINDFULNESS-BASED STRESS REDUCTION IN PATIENTS WITH INTERSTITIAL LUNG DISEASES: A PILOT, SINGLE-CENTRE OBSERVATIONAL STUDY ON SAFETY AND EFFICACY. *BMJ OPEN RESPIR RES.* 2015; 2: e000065.

41. HARARI S, CAMINATI A, ALBERA C, VANCHERI C, POLETTI V, PESCI A, LUPPI F, SALTINI C, AGOSTINI C, BARGAGLI E, SEBASTIANI A, SANDUZZI A, GIUNTA V, DELLA PORTA R, BANDELLI GP, PUGLISI S, TOMASSETTI S, BIFFI A, CERRI S, MARI A, CINETTO F, TIRELLI F, FARINELLI G, BOCCHINO M, SPECCHIA C, CONFALONIERI M. EFFICACY OF PIRFENIDONE FOR IDIOPATHIC PULMONARY FIBROSIS: AN ITALIAN REAL LIFE STUDY. *RESPIR MED.* 2015; 109: 904-913.

42. FERRI C, MANFREDI A, SEBASTIANI M, COLACI M, GIUGGIOLI D, VACCHI C, DELLA CASA G, CERRI S, TORRICELLI P, LUPPI F. INTERSTITIAL PNEUMONIA WITH AUTOIMMUNE FEATURES AND UNDIFFERENTIATED CONNECTIVE TISSUE DISEASE: OUR INTERDISCIPLINARY RHEUMATOLOGY-PNEUMOLOGY EXPERIENCE, AND REVIEW OF THE LITERATURE. *AUTOIMMUN REV.* 2016; 15: 61-70.
43. LOCOCO F, LUPPI F, CERRI S, MONTANARI G, STEFANI A, ROSSI G. PULMONARY CARCINOSARCOMA ARISING IN THE FRAMEWORK OF AN IDIOPATHIC PULMONARY FIBROSIS. *LUNG.* 2016; 194: 171-173.
44. PINI P, BETTUA C, ORSI CF, VENTURELLI C, FORGHIERI F, BIGLIARDI S, FAGLIONI L, LUPPI F, SERIO L, CODELUPPI M, LUPPI M, MUSSINI C, GIRARDIS M, BLASI E. EVALUATION OF SERUM (1 → 3)-B-D-GLUCAN CLINICAL PERFORMANCE: KINETIC ASSESSMENT, COMPARISON WITH GALACTOMANNAN AND EVALUATION OF CONFOUNDING FACTORS. *INFECTION.* 2016; 44: 223-233.
45. DE BIASI S, CERRI S, BIANCHINI E, GIBELLINI L, PERSIANI E, MONTANARI G, LUPPI F, CARBONELLI CM, ZUCCHI L, BOCCHINO M, ZAMPARELLI AS, VANCHERI C, SGALLA G, RICHELDI L, COSSARIZZA A. LEVELS OF CIRCULATING ENDOTHELIAL CELLS ARE LOW IN IDIOPATHIC PULMONARY FIBROSIS AND ARE FURTHER REDUCED BY ANTI-FIBROTIC TREATMENTS. *BMC MED.* 2015; 13: 277
46. SEBASTIANI M, MANFREDI A, CERRI S, DELLA CASA G, LUPPI F, FERRI C. RADIOLOGIC CLASSIFICATION OF USUAL INTERSTITIAL PNEUMONIA IN RHEUMATOID ARTHRITIS-RELATED INTERSTITIAL LUNG DISEASE: CORRELATIONS WITH CLINICAL, SEROLOGICAL AND DEMOGRAPHIC FEATURES OF DISEASE. *CLIN EXP RHEUMATOL.* 2016; 34: 564-565
47. LUPPI F, WELLS AU. INTERSTITIAL PNEUMONITIS WITH AUTOIMMUNE FEATURES (IPAF): A WORK IN PROGRESS. *EUR RESPIR J.* 2016; 47: 1622-1624
48. CERRI S, SGALLA G, RICHELDI L, LUPPI F. OCCURRENCE OF IDIOPATHIC PULMONARY FIBROSIS DURING IMMUNOSUPPRESSIVE TREATMENT: A CASE REPORT. *J MED CASE REP.* 2016; 10: 127
49. MANFREDI A, SEBASTIANI M, CERRI S, CASSONE G, BELLINI P, CASA GD, LUPPI F, FERRI C. PREVALENCE AND CHARACTERIZATION OF NON-SICC A ONSET PRIMARY SJÖGREN SYNDROME WITH INTERSTITIAL LUNG INVOLVEMENT. *CLIN RHEUMATOL.* 2017; 36: 1261-1268
50. JOHANNSON KA, STRÂMBU I, RAVAGLIA C, GRUTTERS JC, VALENZUELA C, MOGULKOC N, LUPPI F, RICHELDI L, WELLS AU, VANCHERI C, KREUTER M; ERICE ILD WORKING GROUP. ANTACID THERAPY IN IDIOPATHIC PULMONARY FIBROSIS: MORE QUESTIONS THAN ANSWERS? *LANCET RESPIR MED.* 2017; 5: 591-598
51. TONELLI R, COCCONCELLI E, LANINI B, ROMAGNOLI I, FLORINI F, CASTANIERE I, ANDRISANI D, CERRI S, LUPPI F, FANTINI R, MARCHIONI A, BEGHÈ B, GIGLIOTTI F, CLINI EM. EFFECTIVENESS OF PULMONARY REHABILITATION IN PATIENTS WITH INTERSTITIAL LUNG

DISEASE OF DIFFERENT ETIOLOGY: A MULTICENTER PROSPECTIVE STUDY. BMC PULM MED. 2017; 17: 130

52. LUPPI F. PREDICTING THE FUTURE OF PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS: ANOTHER STEP FORWARD. LANCET RESPIR MED. 2017; 5: 911-913

53. SVERZELLATI N, ODONE A, SILVA M, POLVEROSI R, FLORIO C, CARDINALE L, CORTESE G, ADDONISIO G, ZOMPATORI M, DALPIAZ G, PICIUCCHI S, LARICI AR; ITALIAN STRUCTURED REPORT ON FIBROSING LUNG DISEASE CONSORT. STRUCTURED REPORTING FOR FIBROSING LUNG DISEASE: A MODEL SHARED BY RADIOLOGIST AND PULMONOLOGIST. RADIOL MED. 2018; 123: 245-253

54. FERRARA G, LUPPI F, BIRRING SS, CERRI S, CAMINATI A, SKÖLD M, KREUTER M. BEST SUPPORTIVE CARE FOR IDIOPATHIC PULMONARY FIBROSIS: CURRENT GAPS AND FUTURE DIRECTIONS. EUR RESPIR REV. 2018 FEB 7; 27 (147).

55. HARARI S, CAMINATI A, POLETTI V, CONFALONIERI M, GASPARINI S, LACEDONIA D, LUPPI F, PESCI A, SEBASTIANI A, SPAGNOLO P, VANCHERI C, BALESTRO E, BONIFAZI M, CERRI S, DE GIACOMI F, DELLA PORTA R, FOSCHINO BARBARO MP, FUI A, PASQUINELLI P, ROSSO R, TOMASSETTI S, SPECCHIA C, ROTTOLI P FOR THE ILDINET (INTERSTITIAL LUNG DISEASES ITALIAN NETWORK). A REAL-LIFE MULTICENTER NATIONAL STUDY ON NINTEDANIB IN SEVERE IDIOPATHIC PULMONARY FIBROSIS. RESPIRATION. 2018 MAR 27

56. MARCHIONI A, TONELLI R, BALL L, FANTINI R, CASTANIERE I, CERRI S, LUPPI F, MALERBA M, PELOSI P, CLINI E. ACUTE EXACERBATION OF IDIOPATHIC PULMONARY FIBROSIS: LESSONS LEARNED FROM THE ACUTE RESPIRATORY DISTRESS SYNDROME? CRITICAL CARE. 2018; 22(1): 80

57. PANCALDI F, SEBASTIANI M, CASSONE G, LUPPI F, CERRI S, DELLA CASA G, MANFREDI A. ANALYSIS OF PULMONARY SOUNDS FOR THE DIAGNOSIS OF INTERSTITIAL LUNG DISEASES SECONDARY TO RHEUMATOID ARTHRITIS. COMPUT BIOL MED. 2018; 96: 91-97

58. BIONDINI D, BALESTRO E, LACEDONIA D, CERRI S, MILANESCHI R, LUPPI F, COCCONCELLI E, BAZZAN E, CLINI E, FOSCHINO BARBARO MP, GREGORI D, COSIO MG, SAETTA M, SPAGNOLO P. PRETREATMENT RATE OF DECAY IN FORCED VITAL CAPACITY PREDICTS LONG-TERM RESPONSE TO PIRFENIDONE IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS. SCI REP. 2018; 8: 5961

59. SGALLA G, WALSH SLF, SVERZELLATI N, FLETCHER S, CERRI S, DIMITROV B, NIKOLIC D, BARNEY A, PANCALDI F, LARCHER L, LUPPI F, JONES MG, DAVIES D, RICHELDI L. "VELCRO-TYPE" CRACKLES PREDICT SPECIFIC RADIOLOGIC FEATURES OF FIBROTIC INTERSTITIAL LUNG DISEASE. BMC PULM MED. 2018 JUN 18;18(1):103

60. FERRI C, ARTONI E, SIGHINOLFI GL, LUPPI F, ZELEN G, COLACI M, GIUGGIOLI D. HIGH SERUM LEVELS OF SILICA NANOPARTICLES IN SYSTEMIC SCLEROSIS PATIENTS WITH OCCUPATIONAL EXPOSURE: POSSIBLE PATHOGENETIC ROLE IN DISEASE PHENOTYPES. SEMIN ARTHRITIS RHEUM. 2018 DEC;48(3):475-481

61. HOLTZE C, FLAHERTY K, KREUTER M, LUPPI F, MOUA T, VANCHERI C, SCHOLAND MB. HEALTHCARE UTILISATION AND COSTS IN THE DIAGNOSIS AND TREATMENT OF PROGRESSIVE-FIBROSING INTERSTITIAL LUNG DISEASES. EUR RESPIR REV. 2018 DEC 21;27(150). pii: 180078

62. HARARI S, CAMINATI A, CONFALONIERI M, POLETTI V, VANCHERI C, PESCI A, ROGLIANI P, LUPPI F, AGOSTINI C, ROTTOLI P, SANDUZZI ZAMPARELLI A, SEBASTIANI A, DELLA PORTA R, SALTON F, MESSORE B, TOMASSETTI S, ROSSO R, BIFFI A, PUXEDDU E, CERRI S, CINETTO F, REFINI RM, BOCCHINO M, DI MICHELE L, SPECCHIA C, ALBERA C; ILDINET (INTERSTITIAL LUNG DISEASES ITALIAN NETWORK). THE PROGNOSTIC ROLE OF GENDER-AGE-PHYSIOLOGY SYSTEM IN IDIOPATHIC PULMONARY FIBROSIS PATIENTS TREATED WITH PIRFENIDONE. CLIN RESPIR J. 2019; 13: 166-173

63. MANFREDI A, SEBASTIANI M, CERRI S, VACCHI C, TONELLI R, DELLA CASA G, CASSONE G, SPINELLA A, FABRIZIO P, LUPPI F, SALVARANI C. ACUTE EXACERBATION OF INTERSTITIAL LUNG DISEASES SECONDARY TO SYSTEMIC RHEUMATIC DISEASES: A PROSPECTIVE STUDY AND REVIEW OF THE LITERATURE. J THORAC DIS. 2019 APR;11(4):1621-1628

64. MANFREDI A, CASSONE G, CERRI S, VENERITO V, FEDELE AL, TREVISANI M, FURINI F, ADDIMANDA O, PANCALDI F, DELLA CASA G, D'AMICO R, VICINI R, SANDRI G, TORRICELLI P, CELENTANO I, BORTOLUZZI A, MALAVOLTA N, MELICONI R, IANNONE F, GREMESE E, LUPPI F, SALVARANI C, SEBASTIANI M; GISEA (GRUPPO ITALIANO STUDIO EARLY ARTHRITIS). DIAGNOSTIC ACCURACY OF A VELCRO SOUND DETECTOR (VECTOR) FOR INTERSTITIAL LUNG DISEASE IN RHEUMATOID ARTHRITIS PATIENTS: THE INSPIRATE VALIDATION STUDY (INTERSTITIAL PNEUMONIA IN RHEUMATOID ARTHRITIS WITH AN ELECTRONIC DEVICE). BMC PULM MED. 2019 JUN 20;19(1):111

65. CERRI S, FONTANA M, BALDUZZI S, POTENZA L, FAVERIO P, LUPPI M, D'AMICO R, SPAGNOLO P, CLINI E, LUPPI F. CLINICAL DIFFERENCES IN SARCOIDOSIS PATIENTS WITH AND WITHOUT LYMPHOMA: A SINGLE-CENTRE RETROSPECTIVE COHORT ANALYSIS. EUR RESPIR J. 2019 NOV 21;54(5). pii: 1802470

66. BEHR J, KOLB M, SONG JW, LUPPI F, SCHINZEL B, STOWASSER S, QUARESMA M, MARTINEZ FJ. NINTEDANIB AND SILDENAFIL IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS AND RIGHT HEART DYSFUNCTION. A PRESPECIFIED SUBGROUP ANALYSIS OF A DOUBLE-BLIND RANDOMIZED CLINICAL TRIAL (INSTAGE). AM J RESPIR CRIT CARE MED. 2019 DEC 15;200(12):1505-1512

67. VANCHERI C, SEBASTIANI A, TOMASSETTI S, PESCI A, ROGLIANI P, TAVANTI L, LUPPI F, HARARI S, ROTTOLI P, GHIRARDINI A, KIRCHGAESSLER KU, ALBERA C. PIRFENIDONE IN REAL LIFE: A RETROSPECTIVE OBSERVATIONAL MULTICENTRE STUDY IN ITALIAN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS. RESPIR MED. 2019 SEP;156:78-84.

68. FAVERIO P, DE GIACOMI F, MESSINESI G, FUMAGALLI A, LUPPI F. EARLY REFERRAL TO PALLIATIVE CARE SERVICES IN PATIENTS WITH IPF: A TOOL TO TAKE A STEP FORWARD. BMJ SUPPORT PALLIAT CARE. 2019 AUG 29. pii: BMJSPCARE-2019-001980

69. CASILLO V, CERRI S, CIERVO A, STENDARDO M, MANZOLI L, FLACCO ME, MANNO M, BOCCHINO M, LUPPI F, BOSCHETTO P. ANTIFIBROTIC TREATMENT RESPONSE AND PROGNOSTIC PREDICTORS IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS AND EXPOSED TO OCCUPATIONAL DUST. BMC PULM MED. 2019 SEP 5;19(1):170
70. CERRI S, MONARI M, GUERRIERI A, DONATELLI P, BASSI I, GARUTI M, LUPPI F, BETTI S, BANDELLI G, CARPANO M, BACCHI REGGIANI ML, TONELLI R, CLINI E, NAVA S. REAL-LIFE COMPARISON OF PIRFENIDONE AND NINTEDANIB IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS: A 24-MONTH ASSESSMENT. RESPIR MED. 2019 NOV;159:105803
71. CERRI S, TONELLI R, FAVERIO P, SVERZELLATI N, CLINI E, LUPPI F. JANUS-FACED AMIODARONE-INDUCED PNEUMOPATHY. PULMONOLOGY. 2020 MAR - APR;26(2):101-103
72. KALLURI M, LUPPI F, FERRARA G. WHAT PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS AND CAREGIVERS WANT: FILLING THE GAPS WITH PATIENT REPORTED OUTCOMES AND EXPERIENCE MEASURES. AM J MED. 2020 MAR;133(3):281-289
73. SEBASTIANI M, CASSONE G, DE PASQUALE L, CERRI S, DELLA CASA G, VACCHI C, LUPPI F, SALVARANI C, MANFREDI A. INTERSTITIAL PNEUMONIA WITH AUTOIMMUNE FEATURES: A SINGLE CENTER PROSPECTIVE FOLLOW-UP STUDY. AUTOIMMUN REV. 2020 FEB;19(2):102451
74. MARCHIONI A, TONELLI R, ROSSI G, SPAGNOLO P, LUPPI F, CERRI S, COCCONCELLI E, PELLEGRINO MR, FANTINI R, TABBÌ L, CASTANIERE I, BALL L, MALBRAIN MLNG, PELOSI P, CLINI E. VENTILATORY SUPPORT AND MECHANICAL PROPERTIES OF THE FIBROTIC LUNG ACTING AS A "SQUISHY BALL". ANN INTENSIVE CARE. 2020 FEB 4;10(1):13
75. SGALLA G, LO GRECO E, CALVELLO M, VARONE F, IOVENE B, CERRI S, DONATELLI P, VANCHERI A, PAVONE M, LUPPI F, VANCHERI C, RICHELDI L. DISEASE PROGRESSION ACROSS THE SPECTRUM OF IDIOPATHIC PULMONARY FIBROSIS: A MULTICENTRE STUDY. RESPIROLOGY. 2020 MAR 19.
76. CASSONE G, MANFREDI A, VACCHI C, LUPPI F, COPPI F, SALVARANI C, SEBASTIANI M. TREATMENT OF RHEUMATOID ARTHRITIS-ASSOCIATED INTERSTITIAL LUNG DISEASE: LIGHTS AND SHADOWS. J CLIN MED. 2020 APR 10;9(4). pii: E1082
77. SEBASTIANI M, MANFREDI A, VACCHI C, CASSONE G, FAVERIO P, CAVAZZA A, SVERZELLATI N, SALVARANI C, LUPPI F. EPIDEMIOLOGY AND MANAGEMENT OF INTERSTITIAL LUNG DISEASE IN ANCA-ASSOCIATED VASCULITIS. CLIN EXP RHEUMATOL. 2020 APR 22
78. MOOR CC, KREUTER M, LUPPI F, WUYTS WA. THE WORLD IS NOT ENOUGH - THE VALUE OF INCREASING REGISTRY DATA IN IDIOPATHIC PULMONARY FIBROSIS. RESPIR RES. 2020 MAY 6;21(1):105.
79. COCCONCELLI E, TONELLI R, ABBATI G, MARCHIONI A, CASTANIERE I, PELIZZARO F, RUSSO FP, VEGETTI A, BALESTRO E, PIETRANGELO A, RICHELDI L, LUPPI F, SPAGNOLO P,

CLINI E, CERRI S. SUBCLINICAL LIVER FIBROSIS IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS. INTERN EMERG MED. 2021 MAR;16(2):349-357

80. FAVERIO P, COMPAGNONI MM, DELLA ZOPPA M, PESCI A, CANTARUTTI A, MERLINO L, LUPPI F, CORRAO G. REHOSPITALIZATION FOR PNEUMONIA AFTER FIRST PNEUMONIA ADMISSION: INCIDENCE AND PREDICTORS IN A POPULATION-BASED COHORT STUDY. PLOS ONE. 2020 JUN 30;15(6):e0235468.

81. FAVERIO P, KALLURI M, LUPPI F, FERRARA G. RA-ILD: DOES MORE DETAILED RADIOLOGICAL CLASSIFICATION ADD SOMETHING TO OUR KNOWLEDGE OF THIS CONDITION? J THORAC DIS. 2020 JUN;12(6):2993-2995.

82. MANFREDI A, LUPPI F, CASSONE G, VACCHI C, SALVARANI C, SEBASTIANI M. PATHOGENESIS AND TREATMENT OF IDIOPATHIC AND RHEUMATOID ARTHRITIS-RELATED INTERSTITIAL PNEUMONIA. THE POSSIBLE LESSON FROM COVID-19 PNEUMONIA. EXPERT REV CLIN IMMUNOL. 2020 AUG;16(8):751-770.

83. LUPPI F, SEBASTIANI M, SVERZELLATI N, CAVAZZA A, SALVARANI C, MANFREDI A. LUNG COMPLICATIONS OF SJOGREN SYNDROME. EUR RESPIR REV. 2020 AUG 18;29(157):200021.

84. DEI G, REBORA P, CATALANO M, SEBASTIANI M, FAVERIO P, POZZI MR, MANFREDI A, CAMELI P, SALTON F, SALVARANI C, CAVAGNA L, CONFALONIERI M, BARGAGLI E, LUPPI F, PESCI A. FUNCTIONAL PROGRESSION IN PATIENTS WITH INTERSTITIAL LUNG DISEASE RESULTED POSITIVE TO ANTISYNTHEASE ANTIBODIES: A MULTICENTER, RETROSPECTIVE ANALYSIS. J CLIN MED. 2020 SEP 21;9(9):3033.

85. LUPPI F, SEBASTIANI M, SILVA M, SVERZELLATI N, CAVAZZA A, SALVARANI C, MANFREDI A. INTERSTITIAL LUNG DISEASE IN SJOGREN SYNDROME: A CLINICAL REVIEW. CLIN EXP RHEUMATOL. 2020 JUL-AUG;38 SUPPL 126(4):291-300.

86. MANFREDI A, SEBASTIANI M, CERRI S, VACCHI C, TONELLI R, DELLA CASA G, CASSONE G, SPINELLA A, PANCALDI F, LUPPI F, SALVARANI C. ERRATUM TO ACUTE EXACERBATION OF INTERSTITIAL LUNG DISEASES SECONDARY TO SYSTEMIC RHEUMATIC DISEASES: A PROSPECTIVE STUDY AND REVIEW OF THE LITERATURE. J THORAC DIS. 2020 OCT;12(10):6411.

87. FAVERIO P, PILUSO M, DE GIACOMI F, DELLA ZOPPA M, CASSANDRO R, HARARI S, LUPPI F, PESCI A. PROGRESSIVE FIBROSING INTERSTITIAL LUNG DISEASES: PREVALENCE AND CHARACTERIZATION IN TWO ITALIAN REFERRAL CENTERS. RESPIRATION. 2020;99(10):838-845.

88. SEBASTIANI M, FAVERIO P, MANFREDI A, CASSONE G, VACCHI C, STAINER A, POZZI MR, SALVARANI C, PESCI A, LUPPI F. INTERSTITIAL PNEUMONIA WITH AUTOIMMUNE FEATURES: WHY RHEUMATOLOGIST-PULMONOLOGIST COLLABORATION IS ESSENTIAL. BIOMEDICINES. 2020 DEC 26;9(1):17

89. POLETTI V, VANCHERI C, ALBERA C, HARARI S, PESCI A, METELLA RR, CAMPOLO B, CRESPI G, RIZZOLI S; FIBRONET STUDY GROUP CLINICAL COURSE OF IPF IN ITALIAN

PATIENTS DURING 12 MONTHS OF OBSERVATION: RESULTS FROM THE FIBRONET OBSERVATIONAL STUDY. RESPIR RES. 2021 FEB 24;22(1):66.

90. SEBASTIANI M, MANFREDI A, FAVERIO P, SALVARANI C, LUPPI F. INTERSTITIAL LUNG DISEASE IN ANCA-ASSOCIATED VASCULITIS: ANOTHER STEP FORWARD. CLIN EXP RHEUMATOL. 2021;39 SUPPL 129 (2):193

91. SEBASTIANI M, MANFREDI A, CASSONE G, SALVARANI C, LUPPI F. REPLY TO THE COMMENT ON: HYPEREOSINOPHILIC BRONCHIOLITIS IN ANCA-ASSOCIATED VASCULITIS: WHERE DOES IT STAND? BY BILGIN ET AL. CLIN EXP RHEUMATOL. 2021 MAR-APR;39 SUPPL 129(2):197. EPUB 2021 MAR 25.

92. MANFREDI A, CASSONE G, LUPPI F, ATIENZA-MATEO B, CAVAZZA A, SVERZELLATI N, GONZÁLEZ-GAY MA, SALVARANI C, SEBASTIANI. RHEUMATOID ARTHRITIS RELATED INTERSTITIAL LUNG DISEASE. .EXPERT REV CLIN IMMUNOL. 2021 MAY;17(5):485-497.

93. LUPPI F, KALLURI M, FAVERIO P, KREUTER M, FERRARA G. IDIOPATHIC PULMONARY FIBROSIS BEYOND THE LUNG: UNDERSTANDING DISEASES MECHANISMS TO IMPROVE DIAGNOSIS AND MANAGEMENT. RESPIR RES. 2021 APR 17;22(1):109.

94. COLLINS BF, LUPPI F. DIAGNOSIS AND MANAGEMENT OF FIBROTIC INTERSTITIAL LUNG DISEASES. CLIN CHEST MED. 2021 JUN;42(2):321-335.

95. KALLURI M, LUPPI F, VANCHERI A, VANCHERI C, BALESTRO E, VARONE F, MOGULKOC N, CACOPARDO G, BARGAGLI E, RENZONI E, TORRISI S, CALVELLO M, LIBRA A, PAVONE M, BONELLA F, COTTIN V, VALENZUELA C, WIJSENBECK M, BENDSTRUP E; 3RD INTERNATIONAL SUMMIT FOR ILD (ISILD), ERICE COLLABORATORS LISTED BELOW. PATIENT-REPORTED OUTCOMES AND PATIENT-REPORTED OUTCOME MEASURES. EUR RESPIR REV. 2021 MAY 25;30(160):210026.

96. FAVERIO P, DE GIACOMI F, BODINI BD, STAINER A, FUMAGALLI A, BINI F, LUPPI F, ALIBERTI S. NON TUBERCULOUS MYCOBACTERIAL PULMONARY DISEASE: AN INTEGRATED APPROACH BEYOND ANTIBIOTICS. ERJ OPEN RES. 2021 MAY 24;7(2):00574-2020.

97. MANFREDI A, CASSONE G, VACCHI C, PANCALDI F, DELLA CASA G, CERRI S, DE PASQUALE L, LUPPI F, SALVARANI C, SEBASTIANI M. USEFULNESS OF DIGITAL VELCRO CRACKLES DETECTION IN IDENTIFICATION OF INTERSTITIAL LUNG DISEASE IN PATIENTS WITH CONNECTIVE TISSUE DISEASE. ARCH RHEUMATOL. 2020 JUN 25;36(1):19-25.

98. MANFREDI A, VACCHI C, DELLA CASA G, CERRI S, CASSONE G, DI CECCO G, LUPPI F, SALVARANI C, SEBASTIANI M. FIBROSING INTERSTITIAL LUNG DISEASE IN PRIMARY SJOGREN SYNDROME. JOINT BONE SPINE. 2021 JUN 9;88(6):105237.

99. DE GIACOMI F, BONAITI G, MONTANELLI F, DELLA ZOPPA M, MESSINESI G, CARLUCCI A, LUPPI F, PESCI A, FAVERIO P. FEASIBILITY AND CLINICAL IMPACT OF A PORTABLE BI-LEVEL VENTILATION DEVICE IN PATIENTS WITH SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND EXERTIONAL DYSPNEA: PRELIMINARY RESULTS FROM A CLINICAL SERIES. PHYSIOTHER THEORY PRACT. 2021. JUN 22:1-5.

100. STAINER A, FAVERIO P, BUSNELLI S, CATALANO M, DELLA ZOPPA M, MARRUCHELLA A, PESCI A, LUPPI F. MOLECULAR BIOMARKERS IN IDIOPATHIC PULMONARY FIBROSIS: STATE OF THE ART AND FUTURE DIRECTIONS. INT J MOL SCI. 2021 JUN 10;22(12):6255.
101. SEBASTIANI M, LUPPI F, SAMBATARO G, CASTILLO VILLEGAS D, CERRI S, TOMIETTO P, CASSONE G, BOCCHINO M, ATIENZA-MATEO B, CAMELI P, MOYA ALVARADO P, FAVERIO P, BARGAGLI E, VANCHERI C, GONZALEZ-GAY MA, CLINI E, SALVARANI C, MANFREDI A. INTERSTITIAL LUNG DISEASE AND ANTI-MYELOPEROXIDASE ANTIBODIES: NOT A SIMPLE ASSOCIATION. J CLIN MED. 2021 JUN 9;10(12):2548.
102. ORLANDI M, LANDINI N, SAMBATARO G, NARDI C, TOFANI L, BRUNI C, BELLANDORANDONE S, BLAGOJEVIC J, MELCHIORRE D, HUGHES M, DENTON CP, LUPPI F, RUARO B, DELLA CASA F, ROSSI FW, DE LUCA G, CAMPOCHIARO C, SPINICCI M, ZAMMARCHI L, TOMASSETTI S, CAMINATI A, CAVIGLI E, ALBANESI M, MELCHIORRE F, PALMUCCI S, VEGNI V, GUIDUCCI S, MOGGI-PIGNONE A, ALLANORE Y, BARTOLONI A, CONFALONIERI M, DAGNA L, DE COBELLI F, DE PAULIS A, HARARI S, KHANNA D, KUWANA M, TALIANI G, LAVORINI F, MIELE V, MORANA G, PESCI A, VANCHERI C, COLAGRANDE S, MATUCCI-CERINIC M. THE ROLE OF CHEST CT IN DECIPHERING INTERSTITIAL LUNG INVOLVEMENT: SYSTEMIC SCLEROSIS VERSUS COVID-19. RHEUMATOLOGY (OXFORD). 2021 JUL 28. IN PRESS.
103. PAOLA FAVERIO, FABRIZIO LUPPI, PAOLA REBORA, SARA BUSNELLI, ANNA STAINER, MARTINA CATALANO, LUCA PARACHINI, ANNA MONZANI, STEFANIA GALIMBERTI, FRANCESCO BINI, BRUNO DINO BODINI, MONIA BETTI, FEDERICA DE GIACOMI, PAOLO SCARPAZZA, ELISA OGGIONNI, ALESSANDRO SCARTABELLATI, LUCA BILUCAGLIA, PAOLO CERUTI, DENISE MODINA, SERGIO HARARI, ANTONELLA CAMINATI, MARIA GRAZIA VALSECCHI, GIACOMO BELLANI, GIUSEPPE FOTI, ALBERTO PESCI. SIX-MONTH PULMONARY IMPAIRMENT AFTER SEVERE COVID-19: A PROSPECTIVE, MULTICENTER FOLLOW-UP STUDY. RESPIRATION. IN PRESS.
104. FAVERIO P, STAINER A, CONTI S, MADOTTO F, DE GIACOMI F, DELLA ZOPPA M, VANCHERI A, PELLEGRINO MR, TONELLI R, CERRI S, CLINI EM, MANTOVANI LG, PESCI A, LUPPI F. DIFFERENCES BETWEEN ACUTE EXACERBATIONS OF IDIOPATHIC PULMONARY FIBROSIS AND OTHER INTERSTITIAL LUNG DISEASES. DIAGNOSTICS (BASEL). 2021 SEP 6;11(9):1623
105. POZZI MR, FAVERIO P, VARISCO V, D'ANDREA G, GIUFFRIDA AC, LUPPI F. INTERSTITIAL PNEUMONIA ASSOCIATED WITH AUTOIMMUNE DISEASES: A POSSIBLE MIMICKER OF SARS-CoV-2 PNEUMONIA. INTERN EMERG MED. 2021 OCT 12:1-5.
106. FAVERIO P, ORNAGHI S, STAINER A, INVERNIZZI F, BORELLI M, BRUNETTI F, LA MILIA L, PAOLINI V, RONA R, FOTI G, LUPPI F, VERGANI P, PESCI A. FEASIBILITY OF CPAP APPLICATION AND VARIABLES RELATED TO WORSENING OF RESPIRATORY FAILURE IN PREGNANT WOMEN WITH SARS-CoV-2 PNEUMONIA: EXPERIENCE OF A TERTIARY CARE CENTRE. PLOS ONE. 2021 OCT 19;16(10):e0258754

107. LUPPI F, SEBASTIANI M, SALVARANI C, BENDSTRUP E, MANFREDI A. ACUTE EXACERBATION OF INTERSTITIAL LUNG DISEASE ASSOCIATED WITH RHEUMATIC DISEASE. NAT REV RHEUMATOL. 2022 FEB;18(2):85-96
108. VANCHERI C, LUPPI F. IDENTIFYING THE RISK OF ACUTE EXACERBATION IN IDIOPATHIC PULMONARY FIBROSIS: A STEP FORWARD. AM J RESPIR CRIT CARE MED. 2022 MAR 1;205(5):489-491.
109. FAVERIO P, REBORA P, ROSSI E, DEL GIUDICE S, MONTANELLI F, GARZILLO L, BUSNELLI S, LUPPI F, VALSECCHI MG, PESCI A. IMPACT OF N-ACETYL-L-CYSTEINE ON SARS-COV-2 PNEUMONIA AND ITS SEQUELAE: RESULTS FROM A LARGE COHORT STUDY. ERJ OPEN RES. 2021 FEB 7;8(1):00542-2021
110. CAVAGNA L, MELONI F, MEYER A, SAMBATARO G, BELLATO M, DE LANGHE E, CAVAZZANA I, PIPITONE N, TRIANTAFYLLIAS K, MOSCA M, BARSOTTI S, ZAMPOGNA G, BIGLIA A, EMMI G, DE VISSER M, VAN DER KOOI A, PARRONCHI P, HIRSCHI S, DA SILVA JAP, SCIRÈ CA, FURINI F, GIANNINI M, MARTINEZ GONZALEZ O, DAMIAN L, PIETTE Y, SMITH V, MERA-VALERA A, BACHILLER-CORRAL J, CABEZAS RODRIGUEZ I, BRANDY-GARCIA AM, MAURIER F, PERRIN J, GONZALEZ-MORENO J, DROTT U, DELBRUCK C, SCHWARTING A, ARRIGONI E, SEBASTIANI GD, IULIANO A, NANNINI C, QUARTUCCIO L, RODRIGUEZ CAMBRON AB, BLÁZQUEZ CAÑAMERO MÁ, VILLA BLANCO I, CAGNOTTO G, PESCI A, LUPPI F, DEI G, ROMERO BUENO FI, FRANCESCHINI F, CHIAPPAROLI I, ZANFRAMUNDO G, LETTIERI S, DE STEFANO L, CUTOLO M, MATHIEU A, PIGA M, PRIETO-GONZÁLEZ S, MORAES-FONTES MF, FONSECA JE, JOVANI V, RICCIERI V, SANTANIELLO A, MONTFORT S, BILOCCA D, ERRE GL, BARTOLONI E, GERLI R, MONTI MC, LORENZ HM, SAMBATARO D, BELLANDO RANDONE S, SCHNEIDER U, VALENZUELA C, LOPEZ-MEJIAS R, CIFRIAN J, MEJIA M, GONZALEZ PEREZ MI, WENDEL S, FORNARO M, DE LUCA G, ORSOLINI G, ROSSINI M, DIEUDE P, KNITZA J, CASTAÑEDA S, VOLL RE, ROJAS-SERRANO J, VALENTINI A, VANCHERI C, MATUCCI-CERINIC M, FEIST E, CODULLO V, IANNONE F, DISTLER JH, MONTECUCCO C, GONZALEZ-GAY MA; AENEAS COLLABORATIVE GROUP. CLINICAL SPECTRUM TIME COURSE IN NON-ASIAN PATIENTS POSITIVE FOR ANTI-MDA5 ANTIBODIES. CLIN EXP RHEUMATOL. 2022 FEB;40(2):274-283
111. FAVERIO P, FUMAGALLI A, CONTI S, MADOTTO F, BINI F, HARARI S, MONDONI M, OGGIONNI T, BARISONE E, CERUTI P, PAPETTI MC, BODINI BD, CAMINATI A, VALENTINO A, CENTANNI S, NOÈ D, DELLA ZOPPA M, CROTTI S, GROSSO M, SUKKAR SG, MODINA D, ANDREOLI M, NICALI R, SUIGO G, DE GIACOMI F, BUSNELLI S, CATTANEO E, MANTOVANI LG, CESANA G, PESCI A, LUPPI F. NUTRITIONAL ASSESSMENT IN IDIOPATHIC PULMONARY FIBROSIS: A PROSPECTIVE MULTICENTER STUDY. ERJ OPEN RES. 2022 MAR 7;8(1):00443-2021
112. FAVERIO P, LUPPI F, REBORA P, D'ANDREA G, STAINER A, BUSNELLI S, CATALANO M, MODAFFERI G, FRANCO G, MONZANI A, GALIMBERTI S, SCARPAZZA P, OGGIONNI E, BETTI M, OGGIONNI T, DE GIACOMI F, BINI F, BODINI BD, PARATI M, BILUCAGLIA L, CERUTI P, MODINA D, HARARI S, CAMINATI A, INTOTERO M, SERGIO P, MONZILLO G, LEATI G, BORGHESI A, ZOMPATORI M, CORSO R, VALSECCHI MG, BELLANI G, FOTI G, PESCI A. ONE-YEAR PULMONARY IMPAIRMENT AFTER SEVERE COVID-19: A PROSPECTIVE, MULTICENTER FOLLOW-UP STUDY. RESPIR RES. 2022 MAR 21;23(1):65

113. SALVARANI C, MASSARI M, COSTANTINI M, FRANCO MERLO D, LUCIA MARIANI G, VIALE P, NAVA S, GUARALDI G, DOLCI G, BONI L, SAVOLDI L, BRUZZI P, TURRÀ C, CATANOSO M, MARIA MARATA A, BARBIERI C, VALCAVI A, FRANZONI F, CAVUTO S, MAZZI G, CORSINI R, TRAPANI F, BARTOLONI A, BARISONE E, BARBIERI C, JOLE BURASTERO G, PAN A, INOJOSA W, SCALA R, BURATTINI C, LUPPI F, CODELUPPI M, ELDIN TAREK K, CENDERELLO G, SALIO M, FOTI G, DONGILLI R, BAJOCCHI G, ALBERTO NEGRI E, CIUSA G, FORNARO G, BASSI I, ZAMMARCHI L, ALOÈ T, FACCIOLONGO N. INTRAVENOUS METHYLPREDNISOLONE PULSES IN HOSPITALISED PATIENTS WITH SEVERE COVID-19 PNEUMONIA. A DOUBLE-BLIND, RANDOMISED PLACEBO-CONTROLLED TRIAL EUR RESPIR J. 2022 MAR 31:2200025
114. FAVERIO P, CONTI S, MADOTTO F, FRANCO G, RENZONI E, MANTOVANI LG, LUPPI F. IDIOPATHIC PULMONARY FIBROSIS MORTALITY IN THE ITALIAN EPICENTER OF COVID-19 PANDEMIC PULMONOLOGY. 2022 APR 12:S2531-0437(22)00084-8.
115. ARIZIO F, BONARDI A, CORTINOVIS D, COSTANZO A, CRISTINZIANO A, DELLE MONACHE L, LANDOLFI R, LETTINO M, LUPPI F, PETRANGOLINI T, TASSIELLI D. PROJECT R. EVOLUTION FOR IMPROVING CLINICAL RESEARCH IN ITALY: CHALLENGES AND STRATEGIES. CURR MED RES OPIN. 2022 JUL 11: 1-9.
116. VAN DEN BOSCH L, LUPPI F, FERRARA G, MURA M. IMMUNOMODULATORY TREATMENT OF INTERSTITIAL LUNG DISEASE. THER ADV RESPIR DIS. 2022 JAN-DEC; 16:17534666221117002
117. FAVERIO P, MONZIO COMPAGNONI M, RONCO R, FRANCHI M, DELLA ZOPPA M, BONAITI G, BONIFAZI M, MEI F, LUPPI F, PESCI A, CORRAO G. ECONOMIC IMPACT OF ANTI-IL-5 AGENTS IN PATIENTS WITH SEVERE EOSINOPHILIC ASTHMA: A POPULATION-BASED COHORT STUDY. J ALLERGY CLIN IMMUNOL PRACT. 2022 AUG 9:S2213-2198(22)00799-1
118. Cameli P, Faverio P, Ferrari K, Bonti V, Marsili S, Mazzei MA, Mazzoni F, Bartolucci M, Scotti V, Bertolini F, Barbieri F, Baldessari C, Veronese C, Boffi R, Brighenti M, Cortinovis D, Dominici M, Pesci A, Bargagli E, Luppi F. Immune-Checkpoint-Inhibitor-Related Lung Toxicity: A Multicentre Real-Life Retrospective Portrait from Six Italian Centres. Life Life (Basel). 2022 Jul 29;12(8):1149.
119. Faverio P, Fumagalli A, Conti S, Madotto F, Bini F, Harari S, Mondoni M, Oggionni T, Barisione E, Ceruti P, Papetti MC, Bodini BD, Caminati A, Valentino A, Centanni S, Lanzi P, Della Zoppa M, Crotti S, Grosso M, Sukkar SG, Modina D, Andreoli M, Nicali R, Suigo G, Busnelli S, Paciocco G, Lettieri S, Mantovani LG, Cesana G, Pesci A, Luppi F. Sarcopenia in idiopathic pulmonary fibrosis: a prospective study exploring prevalence, associated factors and diagnostic approach. Respir Res. 2022 Sep 3;23(1):228
120. Sambataro G, Sambataro D, Spicuzza L, Meloni F, Lorini G, Malatino L, Colaci M, Sebastiani G, Iuliano A, Canofari C, Luppi F, Franco G, Zanini U, Manfredi A, Gozzi F, Sebastiani M, Palmucci S, Cavagna L, Vancheri C. Progression and prognosis of interstitial pneumonia with autoimmune

features: a longitudinal, prospective, multicentre study. Clin Exp Rheumatol. 2022 Oct 3. Online ahead of print.

121. Moitra S, Luppi F. Work-related interstitial lung diseases: reassessing the burden. Int J Tuberc Lung Dis. 2022 Nov 1;26(11):997-998
122. Sambataro G, Palmucci S, Luppi F. Editorial: Multidisciplinary approach to interstitial lung disease associated with systemic rheumatic diseases. Front Med (Lausanne). 2022 Dec 13;9:1112872
123. Faverio P, Conti S, Madotto F, Franco G, Renzoni E, Mantovani LG, Luppi F. Idiopathic pulmonary fibrosis mortality in the Italian epicenter of COVID-19 pandemic. Pulmonology. 2023 Jan-Feb;29(1):85-88.
124. Ferrara MC, Zarcone C, Tassistro E, Rebora P, Rossi E, Luppi F, Foti G, Squillace N, Lettino M, Strepparava MG, Bonfanti P, Bellelli G; STORM Long-COVID Team. Frailty and long-COVID: is COVID-19 responsible for a transition in frailty status among older adults who survived hospitalization for COVID-19? Aging Clin Exp Res. 2023 Feb;35(2):455-461.
125. Squillace N, Cogliandro V, Rossi E, Bellelli G, Pozzi M, Luppi F, Lettino M, Strepparava MG, Ferrarese C, Pollastri E, Ricci E, Bonfanti P; STORM Long-COVID Team. A multidisciplinary approach to screen the post-COVID-19 conditions. BMC Infect Dis. 2023 Jan 24;23(1):54
126. Luppi F, Ferrara G, Faverio P. Fibrotic or nonfibrotic interstitial lung disease in patients with primary Sjogren syndrome. Pol Arch Intern Med. 2023 Feb 27;133(2):16428
127. Faverio P, Fumagalli A, Conti S, Madotto F, Bini F, Harari S, Mondoni M, Oggionni T, Barisione E, Ceruti P, Papetti MC, Bodini BD, Caminati A, Valentino A, Centanni S, Lanzi P, Della Zoppa M, Crotti S, Grosso M, Sukkar SG, Modina D, Andreoli M, Nicali R, Suigo G, Busnelli S, Paciocco G, Lettieri S, Mantovani LG, Cesana G, Pesci A, Luppi F. Short-term evolution of nutritional status in patients with idiopathic pulmonary fibrosis. Ann Am Thorac Soc. 2023 Mar 1
128. Faverio P, Ronco R, Monzio Compagnoni M, Franchi M, Franco G, Bonaiti G, Bonifazi M, Mei F, Luppi F, Pesci A, Corrao G. Effectiveness and economic impact of Dupilumab in asthma: a population-based cohort study.
129. Faverio P, Zanini U, Monzani A, Parati G, Luppi F, Lombardi C, Perger E. Sleep disordered breathing and chronic respiratory infections: a narrative review in adult and pediatric population. Int J Mol. Sci. 2023. In press
130. Ronco R, Franco G, Monzio Compagnoni M, Aliberti S, Luppi F, Corrao G, Faverio P. Healthcare costs and resources utilization in

bronchiectasis versus asthma versus COPD. ERJ Open Research. 2023; 9: 00158-2023

131. Faverio P, Paciocco G, Tassistro E · Rebora P · Emanuela Rossi³ · Monzani A, Tundo M · Milano C, Messa M, Marocchi R, Pesci A, Foti G, Squillace N, Cogliandro V, Lettino M, Strepparava MG, Bellelli G, Ferrarese C, Valsecchi MG, Bonfanti P, Luppi F · The STORM Long-COVID Team. Two-year cardio-pulmonary follow-up after severe COVID-19: a prospective study. Intern. Emerg. Med. 2023. In press
132. Rizzato S, Tacconi M, Andrisani D, Luppi F, Clini E, Cerri S. Bronchiectasis as long-term complication of acute fire smoke inhalation. Pulmonology. 2023 Oct 7: S2531-0437(23)00164-2
133. Marruchella A, Faverio P, Luppi F. Concurrent features of sarcoidosis and hypersensitivity pneumonitis in two patients exposed to fungal antigens. BMC Pulm Med. 2023 Nov 4; 23 (1): 427
134. Cazzaniga ME, Ciaccio A, Danesi R, Duhoux FP, Girmenia C, Zaman K, Lindman H, Luppi F, Mavroudis D, Paris I, Olubukola A, Samreen A, Schem C, Singer C, Snegovoy A. Late onset toxicities associated with the use of CDK 4/6 inhibitors in hormone receptor positive (HR+), human epidermal growth factor receptor-2 negative (HER2-) metastatic breast cancer patients: a multidisciplinary, pan-EU position paper regarding their optimal management. The GIOCONDA project. Front Oncol. 2023 Oct 26; 13: 1247270.
135. Monzio Compagnoni M, Conflitti C, Capuano V, Bonaiti G, Franchi M, Vimercati C, Biondi A, Luppi F, Corrao G, Faverio P. Healthcare costs and resources utilization in children with difficult-to-control asthma treated with biologic therapies: A population-based cohort study. Pediatr Pulmonol. 2023 Nov 22
136. Morlacchi LC, Zanini U, Gramegna A, Faverio P, Blasi F, Luppi F. Idiopathic interstitial pneumonia in a patient with von Hippel-Lindau syndrome: a first case. ERJ Open Res. 2023 Nov 27; 9 (6): 00504-2023
137. Luppi F, Manfredi A, Faverio P, Andersen MB, Bono F, Pagni F, Salvarani C, Bendstrup E, Sebastiani M. The Usual Interstitial Pneumonia Pattern in Autoimmune Rheumatic Diseases. BMC Pulm Med. 2023 Dec 11;23(1):501
138. Zanini U, Luppi F, Kaur K, Anzani N, Franco G, Ferrara G, Kalluri M, Mura M. Use of six-minute walk distance to predict lung transplant-free survival in fibrosing non-IPF interstitial lung diseases.

Respirology. 2024 Feb 6. doi: 10.1111/resp.14669. Online ahead of print

139. Chessari C, Simonetta E, Amati F, Nigro M, Stainer A, Sotgiu G, Puci M, Gramegna A, Blasi F, Morlacchi LC, Buscemi AAMD, Conio V, Sanci V, Corsico AG, Faverio P, Michalak W, Luppi F, Crimi C, Vancheri C, Campisi R, Vulpi MR, Carpagnano GE, Cicchetti M, Sekretna K, Scichilone N, Battaglia S, Aliberti S. Diagnostic delay in bronchiectasis: an italian perspective. *ERJ Open Res.* 2024 Mar 18;10(2):00713-2023.
140. Luppi F, Ferrara G. "A mighty flame can follow a tiny spark": is this the case of C-Jun N-terminal Kinase 1 (JNK) inhibitors in idiopathic pulmonary fibrosis? *Am J Respir Crit Care Med.* 2024 Apr 4
141. Faverio P, Maloberti A, Rebora P, Intravaia RCM, Tognola C, Toscani G, Amato A, Leoni V, Franco G, Vitarelli F, Spiti S, Luppi F, Valsecchi MG, Pesci A, Giannattasio C. Cardiovascular Structural and Functional Parameters in Idiopathic Pulmonary Fibrosis at Disease Diagnosis. *High Blood Press Cardiovasc Prev.* 2024 May 13
142. Faverio P, Sala I, Anzani N, Zanini U, Bonfanti V, Falzone M, Biffi A, Conti S, Mantovani L, Luppi F. Questionnaires May Help Pulmonologists for Referral of Patients With IPF to a Holistic Approach. *Archivos de Bronconeumología.* In press
143. Sebastiani M, Manfredi A, Croci S, Faverio P, Cassone G, Vacchi C, Salvarani C, Luppi F. Rheumatoid arthritis extra-articular lung disease: new insights on pathogenesis and experimental drugs. *Expert Opin Investig Drugs.* 2024 Jul 5: 1-13
144. Faverio P, Franco G, Landoni V, Nadalin M, Negri D, Tagliabue A, Acone F, Cattaneo F, Cipolla F, Vimercati C, Aliberti S, Biondi A and Luppi F. Therapeutic Management of Bronchiectasis in Children and Adolescents: A Concise Narrative Review. *J. Clin. Med.* 2024, 13 (16), 4757
145. Giovanni Franco, Marie-Pierre Debray, Niccolò Anzani, Almerico Marruchella, Aurélie Cazes, Pierre Le Guen, Camille Taillé, Paola Faverio, Raphaël Borie, Fabrizio Luppi, Bruno Crestani. Cystic lung in sarcoidosis: Clinico-radiologic characteristic and evolution. *Respirology.* 2024 Aug 28

146. Luppi, F., Sebastiani, M. Guiding ILD management in systemic autoimmune rheumatic diseases. *Nat Rev Rheumatol* (2024).
147. Zanini U, Ding J, Luppi F, Kaur K, Anzani N, Franco G, Ferrara G, Kalluri M, Mura M. Percent Predicted vs. Absolute Six-Minute Walk Distance as Predictors of Lung Transplant-Free Survival in Fibrosing Interstitial Lung Diseases. *Lung*. 2024 Dec;202(6):793-800.
148. Cavasin D, Zanini U, Montelisciani L, Valsecchi MG, Fabbri L, Antolini L, Luppi F. The impact of COVID-19 infection on idiopathic pulmonary fibrosis mortality: a systematic review and meta-analysis. *Monaldi Arch Chest Dis*. 2024 Oct 15.
149. Luppi F, Manfredi A, Faverio P, Franco G, Salvarani C, Bendstrup E, Sebastiani M. Treatment of acute exacerbation in interstitial lung disease secondary to autoimmune rheumatic diseases: More questions than answers. *Autoimmun Rev*. 2024 Oct 15;23(12):103668
150. Petrella F, Cara A, Cassina EM, Faverio P, Franco G, Libretti L, Pirondini E, Raveglia F, Sibilia MC, Tuoro A, Vaquer S, Luppi F. Evaluation of preoperative cardiopulmonary reserve and surgical risk of patients undergoing lung cancer resection. *Ther Adv Respir Dis*. 2024 Jan-Dec;18:17534666241292488
151. Faghihi-Kashani S, Yoshida A, Bozan F, Zanframundo G, Rozza D, Loganathan A, Dourado E, Sambataro G, Ventura IB, Bae SS, Lim D, Gallegos DR, Yamano Y, Selva-O'Callaghan A, Mammen AL, Scirè CA, Montecucco C, Oddis CV, Fiorentino D, Bonella F, Miller FW, Lundberg IE, Schmidt J, Rojas-Serrano J, Hudson M, Kuwana M, González-Gay MA, McHugh N, Corte TJ, Doyle TJ, Werth VP, Gupta L, Roman DIP, Bianchessi LM, Devarasetti PK, Shinjo SK, Luppi F, Cavazzana I, Moghadam-Kia S, Fornaro M, Volkmann ER, Piga M, Loarce-Martos J, De Luca G, Knitza J, Wolff-Cecchi V, Sebastiani M, Schiffenbauer A, Rider LG, Campanilho-Marques R, Marts L, Bravi E, Gunawardena H; CLASS project participating investigators; Aggarwal R, Cavagna L. Clinical characteristics of antisynthetase syndrome: analysis from the CLASS project. *Arthritis Rheumatol*. 2024 Oct 28.
152. Raimondi F, Centanni S, Luppi F, Aliberti S, Blasi F, Rogliani P, Micheletto C, Contoli M, Sanduzzi Zamparelli A, Bocchino M, Busatto P, Novelli L, Pappacena S, Malandrino L, Lorini G, Cairoli G, Di Marco F. Respiratory rate-oxygenation index on the 3rd day is the best predictor of treatment failure in COVID-19 patients. *Monaldi Arch Chest Dis*. 2024 Oct 24.

153. Manfredi A, Venerito V, Cazzato M, Sambataro G, Zanini U, Gozzi F, Gentileschi Canofari C, Atzeni F, Cassone G, Iannone F, Laurino E, Vancheri, Luppi F, Cerri S and Sebastiani M. Pulmonary Progressive Fibrosis in Rheumatoid Arthritis and Primary Sjogren Syndrome: Similarities and Differences. *J. Clin. Med.* 2024, 13(21), 6508
154. Zanini U, Faverio P, Bonfanti V, Falzone M, Cortinovis D, Arcangeli S, Petrella F, Ferrara G, Mura M, Luppi F. The '*Liaisons dangereuses*' Between Lung Cancer and Interstitial Lung Diseases: A Focus on Acute Exacerbation. *J Clin Med.* 2024 Nov 23;13(23):7085
155. Franco G, Landoni V, Nadalin M, Negri D, Tagliabue A, Acone F, Cattaneo F, Cipolla F, Vimercati C, Aliberti S, Lucchini G, Balduzzi AC, Luppi F, Faverio P, Faverio P. Diagnostic Management of Pediatric Bronchiectasis: A Literature Review and Clinical Examples. *Respiration.* 2025 Apr 24:1-13.
156. Zanini U, Marruchella A, Paciocco G, Bono F, Bonaiti G, Ammatuna F, Faverio P, Luppi F. A rare case of bronchial stenosis in ulcerative colitis. *BMC Pulm Med.* 2025 May 27;25(1):267
157. Petrella F, Faverio P, Cara A, Cassina EM, Libretti L, Torto SL, Pirondini E, Raveglia F, Spinelli F, Tuoro A, Perger E, Luppi F. Clinical Impact of Vaping. *Toxics.* 2025 Jun 1;13(6):470.
158. Faverio P, Rebora P, Franco G, Amato A, Corti N, Cattaneo K, Spiti S, Zanini U, Maloberti A, Giannattasio C, Luppi F, Leoni V. Alteration of Lipid Metabolism in Patients with IPF and Its Association with Disease Severity and Prognosis: A Case-Control Study. *Int J Mol Sci.* 2025 Jun 17;26(12):5790
159. Mondoni M, Varone F, Luppi F, Cameli P, Cerri S, Puci MV, Cefalo J, Contino S, Martini A, Iovene B, Sgalla G, Franco G, Zanini U, Pianigiani T, Dilroba A, Puggioni D, Patsoura A, Mosole B, Torre O, Bargagli E, Richeldi L, Sotgiu G. Effectiveness of Nintedanib in Progressive Pulmonary Fibrosis Assessed by Progression Criteria: An Italian, Observational, Multicenter Study. *Lung.* 2025 Jul 8;203(1):77
160. Park HY, Kong S, Lee M, Ryu H, Hamakawa Y, Luppi F, Leung JM. Digital health technologies for improving the management of people with chronic obstructive pulmonary disease. *Front Digit Health.* 2025 Aug 6;7:1640585

161. Perger E, Parati G, Faini A, Gell L, Faverio P, **Luppi F**, Bertoli S, Brunani A, Bigagli E, Lombardi C, Taranto-Montemurro L. Acetazolamide Plus Atomoxetine for Obesity Hypoventilation Syndrome Treatment. Chest. 2025 Sep 25:S0012-3692(25)05384-X.
162. Petrella F, Luppi F. Functional assessment and clinical staging of patients undergoing lung resection. Ther Adv Respir Dis. 2025 Jan-Dec;19:17534666251386201
- 163.

ARTCOLI ORIGINALI IN RIVISTE INTERNAZIONALI NON INDEXATE

1. D'AMATO G, SANTANGELO G, VINCIGUERRA A, VELLUTI G, COVI M, LUPPI F. STUDIO SULL'EFFICACIA E LA TOLLERABILITÀ DELLA ROKITAMICINA NELLE INFEZIONI SOSTENUTE DA HAEMOPHILUS INFLUENZAE ED ALTRI PATOGENI RESPIRATORI. MINERVA PNEUMOL. 1996; 35: 105-112.
2. LUPPI F AND FABBRI LM. LUNG INJURY MECHANISMS IN COPD. GASLINI. 2001; 33: 160-164.
3. ROMAGNOLI M, PAPI A, LUPPI F AND FABBRI LM. NEW THERAPEUTIC INDICATIONS FOR CYS-LT1 ANTAGONISTS: CHRONIC OBSTRUCTIVE PULMONARY DISEASE. CLIN. EXP. ALL. REV. 2001; 1 (2): 166-169.
4. DEBBI A, LOSI M, LUPPI F, FABBRI LM, RICHELDI L. NUOVI STRUMENTI PER LA DIAGNOSI DI INFEZIONE TUBERCOLARE LATENTE. RASSEGNA DI MALATTIE DELL'APPARATO RESPIRATORIO. 2003; 18: 482-487.
5. LUPPI F, CERRI S, DE CARLO MR, SERINI R, FABBRI LM, L.M. RICHELDI L. THERAPEUTIC APPROACHES TO IDIOPATHIC PULMONARY FIBROSIS. MINERVA PNEUMOL. 2004; 43: 151-164.
6. SCOTTI E, DE PALMA G, MOZZONI P, CARNEVALI S, LUPPI F, CAGLIERI A, VETTORI MV, GOLDONI M, FABBRI L, MUTTI A. IN VITRO CHARACTERIZATION OF HEME OXYGENASE 1 IN HUMAN EPITHELIAL LUNG CELLS EXPOSED TO CIGARETTE SMOKE [CARATTERIZZAZIONE IN VITRO DELL'ESPRESSIONE DELL'EME OSSIGENASI 1 IN CELLULE EPITELIALI POLMONARI UMANE ESPOSTE A FUMO DI SIGARETTA]. GIORNALE ITALIANO DI MEDICINA DEL LAVORO ED ERGONOMIA. 2004; 26 (4 SUPPL.): 103-104
7. LUPPI F, ROMAGNOLI M, FABBRI LM. THE GLOBAL INITIATIVE FOR ASTHMA GUIDELINES: AN UPDATE. EUR. RESPIR. REV. 2004 ; 13: 90, 57-61.
8. ROMAGNOLI M, LUPPI F, CORBETTA L, PAPI A AND FABBRI LM. MANAGEMENT OF FIXED AIRFLOW LIMITATION CAUSED BY ASTHMA OR CHRONIC OBSTRUCTIVE PULMONARY DISEASE. CLIN. EXP. ALL. REV. 2004; 4: 205-211.

9. FABBRI LM, LUPPI F, SAETTA M. PATOGENESI. IN: VITTORIO GRASSI, CARLO GIUNTINI, LEONARDO M. FABBRI. BRONCOPNEUMOPATIA CRONICA OSTRUTTIVA. ANN. ITAL. MED. INT. 2004; 19 (SUPPL 1): 42S-49S.
10. DEBBI A, LOSI M, LUPPI F, FABBRI LM, RICHELDI L. NUOVI STRUMENTI PER LA DIAGNOSI DI INFEZIONE LATENTE. PREVENZIONE RESPIRATORIA. 2003; 2/3: 6-13.
11. RICHELDI L, CERRI S, LUPPI F, FABBRI LM. LA SARCOIDOSI: RECENTI ACQUISIZIONI PER UNA MALATTIA MISTERIOSA. MEDICINA TORACICA. 2005; 3: III-XVII.
12. ZENI E, QUINTAVALLE S, CARNEVALI, S, LO CASCIO N, LUPPI F, MAPP CE, DE ROSA E, BOSCHETTO P. CHROMIUM (VI) INCREASES MUC5AC MUCIN PRODUCTION IN CULTURED HUMAN AIRWAY EPITHELIAL CELLS [IL CROMO (VI) AUMENTA LA SECREZIONE DI MUCINA MUC5AC IN COLTURE DI CELLULE EPITELIALI BRONCHIALI UMANE]. GIORNALE ITALIANO DI MEDICINA DEL LAVORO ED ERGONOMIA. 2006; 28: 320-321
13. LUPPI F, RICHELDI L. PHARMACOLOGICAL TREATMENT OF IPF EXACERBATION. RASSEGNA DI PATOLOGIA DELL'APPARATO RESPIRATORIO. 2008; 23: 350-353
14. LUPPI, F., BEGHÈ, B., ROVERSI, P. INFECTIONS AS COMORBIDITY OF COPD [LE INFEZIONI COME COMORBILITÀ DELLA BPCO]. ITALIAN JOURNAL OF MEDICINE. 2011; 5(1 SUPPL. 1): S135-S141
15. CORBETTA, L, LUPPI, F., INCALZI, R.A. GUIDELINES ON COPD NOT ASSOCIATED WITH CHRONIC COMORBIDITY [LINEE GUIDA SULLA BPCO NON ASSOCIATE A COMORBILITÀ CRONICHE]. ITALIAN JOURNAL OF MEDICINE. 2011; 5(1 SUPPL. 1): S14-S21
16. LUPPI, F., BEGHÈ, B., ROVERSI, P. PULMONARY COMORBIDITIES ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE [BPCO E ALTRE MALATTIE POLMONARI CRONICHE]. ITALIAN JOURNAL OF MEDICINE. 2012; 6: 265-275
17. LUPPI, F., CERRI, S., SGALLA, G., RICHELDI, L. CHALLENGES IN IDIOPATHIC INTERSTITIAL LUNG DISEASE. MINERVA PNEUMOLOGICA. 2015; 54: 183-192
18. CERRI S, LUPPI F. PERSONALIZED MEDICINE AND IDIOPATHIC PULMONARY FIBROSIS [MEDICINA PERSONALIZZATA E FIBROSI POLMONARE IDIOPATICA]. RASSEGNA DI PATOLOGIA DELL'APPARATO RESPIRATORIO. 2015; 30: 327-334

CAPITOLI SU TRATTATI, MONOGRAFIE ED ATTI NAZIONALI ED INTERNAZIONALI

1. LUPPI F, COVI M, CAPELLI O, VELLUTI G. IL LAVAGGIO BRONCO-ALVEOLARE (BAL) NELLA PRATICA CLINICA. IN: AGGIORNAMENTI DI RADIOLOGIA TORACICA. VOLUME XII. APC-SIRM. 1997, PAGG. 97-99.
2. VELLUTI G, LUPPI F, COVI M, MOSCARA G, M.E. BONUCCHI, R. RONCAGLIA, E. BALDINI. ANION SUPEROXIDE PRODUCTION, PHAGOCYTOSIS AND INTRACELLULAR KILLING IN IDIOPATHIC PULMONARY FIBROSIS AND IN ACQUIRED IMMUNODEFICIENCY SYNDROME. IN:

ADVANCES IN FREE RADICALS IN DISEASE. (PIZZALA R, TOMASI A, VANNINI V EDS). LA GOLIARDICA PAVESE. IV.1998, PAGG 121-132

3. COVI M, LUPPI F, VELLUTI G. LAVAGGIO BRONCHIOLO-ALVEOLARE. ENCICLOPEDIA MEDICA ITALIANA. AGGIORNAMENTO II. 1999: 3112-3121.

4. COVI M, LUPPI F, VELLUTI G. CARCINOMA A PICCOLE CELLULE (MICROCITOMA): ENCICLOPEDIA MEDICA ITALIANA. AGGIORNAMENTO II. 2000: 4499-4533

5. COVI M, LUPPI F, VELLUTI G. MICOBATTERI TUBERCOLARI MULTIRESISTENTI. ENCICLOPEDIA MEDICA ITALIANA. AGGIORNAMENTO II. 2000: 5989-5998.

6. COVI M, LUPPI F, VELLUTI G. GRANULOMATOSI DI WEGENER. ENCICLOPEDIA MEDICA ITALIANA. AGGIORNAMENTO II. 2000: 6273-6293

7. SALTINI C, GIOSUÈ S, LUPPI F. LE PNEUMOPATIE INTERSTIZIALI. IN: G. CREPALDI, A. BARITUSSIO. TRATTATO DI MEDICINA INTERNA. VOLUME II. ED. PICCIN NUOVA LIBRARIA, PAGG. 1909-1945.

8. LUPPI F, ZUCCHI L. LA DIAGNOSI ALLERGOLOGICA DI ASMA. IN: ASMA BRONCHIALE. EDITOR: L.M. FABBRI. EDI-AIPO SCIENTIFICA EDITORE, PAGG. 339-352.

9. LUPPI F, DE GUGLIELMO M, FABBRI LM. I FATTORI DI RISCHIO DELL'ASMA BRONCHIALE. IN: ASMA BRONCHIALE. EDITOR: L.M. FABBRI. EDI-AIPO SCIENTIFICA EDITORE, PAGG. 37-61

10. LUPPI F, DE GUGLIELMO M, FABBRI LM. FATTORI DI RISCHIO DELL'ASMA BRONCHIALE. IN: RAPPORTO SULL' ASMA EDITORS: MARIO DE PALMA, LEONARDO M. FABBRI, CARLO GRASSI. EDITORE: SINTAGMA SRL. 2001, PAGG. 48-81

11. SAETTA M, TURATO G, LUPPI F, FABBRI LM. INFLAMMATION IN THE PATHOGENESIS OF COPD. IN: CHRONIC OBSTRUCTIVE PULMONARY DISEASE. EDITORS: N. VOELKEL, W. MAC NEE. BC DECKER INC PUBLISHER. 2002, PAGG. 114-126.

12. FABBRI LM, LUPPI F, ROMAGNOLI M, CORBETTA L. ASTHMA VERSUS COPD : CELLULAR AND MOLECULAR DIFFERENCES. IN: COPD CELLULAR AND MOLECULAR MECHANISMS. EDITOR: PETER J BARNES. LUNG BIOLOGY IN HEALTH AND DISEASE SERIES: EDITED BY CLAUDE LENFANT. MARCEL DEKKER, INC. PUBLISHER. 2005, PAGG. 55-81

13. LUPPI F, FABBRI LM. DEFINIZIONE, CLASSIFICAZIONE ED EZIOPATOGENESI. CAPITOLO 1. IN: RAPPORTO SULLA BRONCOPNEUMOPATIA CRONICA OSTRUTTIVA (BPCO). EDITORS: MARIO DE PALMA E LEONARDO M. FABBRI. 2005, PAGG. 10 -19.

14. BEGHE B, LUPPI F, FABBRI LM. PHARMACOLOGICAL PREVENTION OF COPD EXACERBATIONS. IN: CHRONIC OBSTRUCTIVE PULMONARY DISEASE EXACERBATIONS. MARCELL DEKKER NEW YORK USA. 2008, PAGG. 341-355

15. LUPPI F, BEGHE B, CORBETTA L, FABBRI LM. DIAGNOSIS OF ASTHMA AND COPD. CHAPTER 41. IN "ASTHMA AND COPD: BASIC MECHANISMS AND CLINICAL MANAGEMENT". ELSEVIER, LTD. 2009, PAGG. 523-541
16. LUPPI F, FABBRI LM. APPROACH TO COPD: RESPIRATORY OR SYSTEMIC TREATMENT? SYSTEMIC APPROACH. IN: COPD IS/IS NOT A SYSTEMIC DISEASE? NOVA SCIENCE PUBLISHERS, INC. 2010, PAGG 181-197
17. LUPPI F, MARCHIONI A, PARDI R, RICHELDI L. POLMONITI. CAPITOLO 17. MALATTIE RESPIRATORIE INFETTIVE. IN: CLAUDIO RUGARLI. "MEDICINA INTERNA SISTEMATICA". SESTA EDIZIONE. ELSEVIER-MASSON. 2010, PAGG. 396-411
18. LUPPI F, SAETTA M, FABBRI LM. BRONCOPNEUMOPATIA CRONICA OSTRUTTIVA. CAPITOLO 18. MALATTIE RESPIRATORIE OSTRUTTIVE. IN: CLAUDIO RUGARLI. "MEDICINA INTERNA SISTEMATICA". SESTA EDIZIONE. ELSEVIER-MASSON. 2010, PAGG. 445-458
19. ROSSI R, LUPPI F, CREMONA G. IPERTENSIONE ARTERIOSA POLMONARE. CAPITOLO 18. MALATTIE RESPIRATORIE OSTRUTTIVE. IN: CLAUDIO RUGARLI. "MEDICINA INTERNA SISTEMATICA". SESTA EDIZIONE. ELSEVIER-MASSON. 2010, PAGG. 530-545
20. FABBRI LM, LUPPI F, BEGHÈ B, RABE KF. MULTIPLE COMPONENTS OF COPD. IN "COPD: A GUIDE TO DIAGNOSIS AND CLINICAL MANAGEMENT". HUMANA PRESS. 2011, PAGG. 1-20.
21. CERRI S, SPAGNOLO P, LUPPI F, RICHELDI L. SMOKING-RELATED INFILTRATIVE LUNG DISEASE. EUROPEAN RESPIRATORY MONOGRAPH. 2011; 54: 282-300.
22. BARALDO S, CAZZUFFI S, BAZZAN E, LUPPI F, TURATO G, SAETTA M. PATHOLOGY OF COPD AND ASTHMA. IN: MECHANICS OF BREATHING: NEW INSIGHTS FROM NEW TECHNOLOGIES: SECOND EDITION. 2014, PAGG. 25-36
23. VERDURI A, LUPPI F, ROVERSI P, FABBRI LM. BRONCOPNEUMOPATIA CRONICA OSTRUTTIVA. IN: TRATTATO DI MALATTIE RESPIRATORIE (A CURA DI LEONARDO M. FABBRI E SERAFINO A. MARSICO). EDISES. 2013, PAGG. 294-309
24. LUPPI F, ROVERSI S, MARCHIONI A, PARDI R, FANTINI R, RICHELDI L. POLMONITI. IN: CLAUDIO RUGARLI. "MEDICINA INTERNA SISTEMATICA". SETTIMA EDIZIONE. EDRA-MASSON. 2015, PAGG. 415-431
25. LUPPI F, SAETTA M, FABBRI LM. BRONCOPNEUMOPATIA CRONICA OSTRUTTIVA. IN: CLAUDIO RUGARLI. "MEDICINA INTERNA SISTEMATICA". SETTIMA EDIZIONE. EDRA-MASSON. 2015, PAGG. 466-482
26. LUPPI F, SPAGNOLO P, RICHELDI L. PNEUMOPATIE INFILTRATIVE DIFFUSE. IN: CLAUDIO RUGARLI. "MEDICINA INTERNA SISTEMATICA". SETTIMA EDIZIONE. EDRA-MASSON. 2015, PAGG. 551-571

27. CERRI S, ORI M, GARUTI M, LUPPI F. BIOMARCATORI. IN: FIBROSI POLMONARE IDIOPATICA (EDITOR: LUCA RICHELDI). DYNAMICON EDIZIONI. 2016, PAGG. 41-54
28. ALBERA C, CERRI S, LUPPI F, RICHELDI L, ROGLIANI P, SPAGNOLO P. MALATTIE INFILTRATIVE DIFFUSE DEL POLMONE. IN: MANUALE DI PNEUMOLOGIA (EDITORS: ENRICO MARIA CLINI E GIROLAMO PELAIA). EDISES EDIZIONI. 2017, PAGG. 215-229
29. CERRI S, SPAGNOLO P, LUPPI F, SGALLA G, RICHELDI L. MANAGEMENT OF IDIOPATHIC PULMONARY FIBROSIS. IN: INTERSTITIAL LUNG DISEASE. ELSEVIER. 2017, PAGG. 55-63
30. LUPPI F, FAVERIO P, WUYTS W. MULTIDISCIPLINARY APPROACH TO SYSTEMIC DISEASES: BENEFITS FOR DIAGNOSIS AND MANAGEMENT OF COMPLEX DISORDERS. IN: WUYTS WA, COTTIN V, SPAGNOLO P, AND WELLS AU. PULMONARY MANIFESTATIONS OF SYSTEMIC DISEASES (ERS MONOGRAPH). SHEFFIELD, EUROPEAN RESPIRATORY SOCIETY, 2019; PP. 1-13.

"AUTORIZZO IL TRATTAMENTO DEI MIEI DATI PERSONALI CONTENUTI NEL CV AI SENSI DEL D. LGS. 196/2003 "CODICE IN MATERIA DI PROTEZIONE DEI DATI PERSONALI" E DEL GDPR (REGOLAMENTO UE 2016/679) MONZA, 09.08.2023

MONZA, 05.05.2025

